RxDoctor Payments DataLook up a doctor →

Carl Dukes, MD

Nephrology · San Antonio, TXNPI 1154334464

Payments from drug & device makers

$5,891,162in general payments, 2019–2025

Across 3,147 payments — averaging $1871.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1.4M
  • AstraZeneca$784K
  • Regeneron$712K
  • Novo Nordisk AS$640K
  • AbbVie$445K
  • Eli Lilly$349K
  • plus $1.5M from 54 others
$45,811in research payments, 2019–2025

Across 10 payments — averaging $4581.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Akebia Therapeutics Inc$27K
  • Eli Lilly$15K
  • Fresenius USA Marketing, Inc.$3K
  • Ardelyx, Inc.$600
  • Novo Nordisk AS$50

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer87$1,411,867
AstraZeneca318$783,936
Regeneron63$711,974
Novo Nordisk AS1,372$639,739
AbbVie(2 entities)163$445,082
Eli Lilly11$348,672
Astrazeneca UK Limited2$279,773
Akebia Therapeutics Inc169$240,357
Vanda Pharmaceuticals Inc.45$169,705
GSK61$168,866
Bristol Myers Squibb19$121,559
Navidea Biopharmaceuticals, Inc.4$90,888
Bausch Health US, LLC7$56,593
Sanofi US Services Inc.18$53,617
Takeda Pharmaceuticals U.S.A., Inc.20$45,346
Ortho-clinical Diagnostics, Inc.7$44,586
Teva Pharmaceuticals USA, Inc.8$41,739
Boehringer Ingelheim Canada Ltd.ltee48$32,712
Genentech, Inc.7$28,747
AMAG Pharmaceuticals, Inc.15$27,168
E.r. Squibb & Sons, L.L.C.3$26,411
Boehringer Ingelheim20$26,395
Amgen(2 entities)92$23,549
Partner Therapeutics, Inc.9$16,929
Vifor (international) Ltd.6$12,094
Bayer73$11,519
Johnson & Johnson23$11,380
Janssen Research & Development, LLC2$3,427
Sanofi Pasteur Inc.2$2,800
Novo Nordisk80$2,477
OPKO Pharmaceuticals, LLC78$1,533
Travere Therapeutics, Inc.34$1,258
Calliditas Therapeutics US Inc.22$979
Lilly USA, LLC39$943
Otsuka America Pharmaceutical, Inc.30$902
Ardelyx, Inc.8$887
Mallinckrodt Hospital Products Inc.28$863
Fresenius USA Marketing, Inc.23$545
Mallinckrodt Enterprises LLC19$429
Vifor Pharma, Inc.10$341
Novartis16$329
Corcept Therapeutics8$311
Abbott4$288
Mannkind Corporation19$274
Cormedix Inc.3$216
ANI Pharmaceuticals, Inc.10$203
Sanofi-aventis U.S. LLC10$197
Aurinia Pharma U.S., Inc.4$164
Esperion Therapeutics, Inc.3$155
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC5$74
Merck4$60
Scpharmaceuticals Inc.2$46
Arbor Pharmaceuticals, Inc.3$45
Xeris Pharmaceuticals, Inc.2$37
Shield Therapeutics Inc2$37
Sanofi1$34
Kowa Pharmaceuticals America, Inc.2$30
Otsuka Pharmaceutical Development & Commercialization, Inc.1$24
Dexcom, Inc.1$22
Amicus Therapeutics, Inc.1$22

How this compares

$5,891,162 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas →

Medicare billing

Part B allowed, 2024
$115,384
Medicare patients
234
Services billed
1,095

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nephrology in San Antonio

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →